PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 66 | 5 | 87–92
Article title

Wpływ tyreoliberyny na ośrodkową regulację układu krążenia

Content
Title variants
EN
Influence of thyroliberin on central cardiovascular regulation
Languages of publication
PL
Abstracts
EN
Thyroliberin (thyrotropin releasing hormone – TRH) is a tripeptide synthesized mainly in the paraventricular nucleus of the hypothalamus. It is a component of the hypothalamic–pituitary–thyroid axis, in which it intensifi es the synthesis and secretion of the thyroid stimulating hormone. It also regulates the release of other hormones (prolactin, vasopressin) and neurotransmitters in the central nervous system (noradrenaline and adrenaline). Acting as a neuromodulator, TRH aff ects many functions of the central nervous system. In the present review, we demonstrate interactions between the thyroliberinergic system and other neuronal systems, especially the role of TRH in the central cardiovascular regulation. The diff erences between TRH-induced eff ects in normotension, hypertension and hypotension have been presented.
PL
Tyreoliberyna (thyrotropin releasing hormone – TRH) to tripeptyd syntetyzowany głównie w jądrze przykomorowym podwzgórza. Jest składową osi podwzgórze–przysadka–tarczyca, w której nasila procesy syntezy i wydzielania hormonu tyreotropowego. Wpływa także na uwalnianie innych hormonów (prolaktyna, wazopresyna) i neuroprzekaźników w ośrodkowym układzie nerwowym (noradrenalina i adrenalina). Działając jako neuromodulator, TRH wpływa na wiele funkcji ośrodkowego układu nerwowego. W pracy przedstawiono współzależności między układem tyreoliberynergicznym a innymi układami neuronalnymi, ze szczególnym uwzględnieniem znaczenia THR w ośrodkowej regulacji układu krążenia. Zwrócono uwagę na różnice w działaniu TRH w stanach normotensji, hipertensji oraz hipotensji.
Discipline
Publisher

Year
Volume
66
Issue
5
Pages
87–92
Physical description
Contributors
  • Katedra i Zakład Podstawowych Nauk Medycznych Wydziału Zdrowia Publicznego Śląskiego Uniwersytetu Medycznego w Katowicach
author
  • Katedra i Zakład Podstawowych Nauk Medycznych Wydziału Zdrowia Publicznego Śląskiego Uniwersytetu Medycznego w Katowicach ul. Piekarska 18 41-902 Bytom tel. +48 32 397 65 42 fax +48 32 397 65 37, jjochem@poczta.onet.pl
References
  • 1. Hollenberg A.N. The role of the thyrotropin- releasing hormone (TRH) neuron as a metabolic sensor. Thyroid 2008; 18: 131–139.
  • 2. de la Pena P., Delgado L.M., del Camino D. i wsp. Cloning and expression of the thyrotropin- releasing hormone receptor from GH3 rat anterior pituitary cells. Biochem. J. 1992; 284: 891–899.
  • 3. Cao J., O’Donnell D., Vu H. i wsp. Cloning and characterization of a cDNA encoding a novel subtype of rat thyrotropin-releasing hormone receptor. J. Biol. Chem. 1998; 273: 32281–32287.
  • 4. Itadani H., Nakamura T., Itoh J. i wsp. Cloning and characterization of a new subtype of thyrotropin releasing receptors. Biochem. Biophys. Res. Commun. 1998; 250: 68–71.
  • 5. Ciosek J. Thyrotropin-releasing hormone (TRH): the biosynthesis, distribution, receptors and metabolism. Endokrynol. Pol. 2004; 55: 608–615.
  • 6. Monga V., Meena C.L., Kaur N., Jain R. Chemistry and biology of thyrotropin- releasing hormone (TRH) and its analogs. Curr. Med. Chem. 2008; 15: 2718–2733.
  • 7. Gary K.A., Sevarino K.A., Yarbrough G.G., Prange A.J., Winokur A. The thyrotropin- releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J. Pharmacol. Exp. Ther. 2003; 305: 410–416.
  • 8. Vetulani J., Nalepa I. Antidepressants: past, presents and future. Eur. J. Pharmacol. 2000; 405: 351–363.
  • 9. Luo L., Stopa E.G. Thyrotropin releasing hormone inhibits tau phosphorylation by dual signaling pathways in hippocampal neurons. J. Alzheimers Dis. 2004; 5: 527–536.
  • 10. Kubek M.J., Garg B.P. Thyrotropin-releasing hormone in the treatment intractable epilepsy. Pediatr. Neurol. 2002; 26: 9–17.
  • 11. Turchi F., Ronconi V., di Tizio V., Boscaro M., Giacchetti G. Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension. Am. J. Hypertens. 2011; 24: 1274–1279.
  • 12. Coupland N.J., Bailey J.E., Glue P., Nutt D.J. The cardiovascular and subjective eff ects of thyrotropin releasing hormone (TRH) and a stable analogue, dimethyl proline-TRH, in healthy volunteers. Br. J. Clin. Pharmacol. 1995; 40: 223–229.
  • 13. Tagliavini S., Bertolini E., Bazzani C., Bertolini A., Guarini S. Infl uence of TRH on regional blood fl ow and metabolic acidosis in a model of volume-controlled hemorrhagic shock in rats. Neuropeptides 1991; 20: 233–238.
  • 14. García S.I., Pirola C.J. Thyrotropinreleasing hormone in cardiovascular pathophysiology. Regul. Pept. 2005; 128: 239–246.
  • 15. Nurminen M.L., Paakkari I., Seppälä T. Serotonergic involvment in the cardiovascular stimulation by thyrotropin-releasing hormone (TRH) in anesthetized rats. Neurosci. Lett. 1991; 127: 147–149.
  • 16. Okuda C., Tanaka H., Miyazaki M. Cardiovascular eff ect of intravenously administered thyrotropin-releasing hormone and its concentration in push-pull perfusion of the fourth ventricle in conscious and and pentobarbital-anasthetized rats. Life Sci. 1988; 42: 1181–1188.
  • 17. García S.I., Alvarez A.L., Porto P.I., Garfunkel V.M., Finkielman S., Pirola C.J. Antisense inhibition of thyrotropin-releasing hormone reduces arterial blood pressure in spontaneously hypertensive rats. Hypertension 2001; 37: 365–370.
  • 18. Suzuki S., Pilowsky P., Minson J., Arnolda L., Llewellyn-Smith I., Chalmers J. Antisense to thyrotropin releasing hormone receptor reduces arterial blood pressure in spontaneously hypertensive rats. Circ. Res. 1995; 77: 679–683.
  • 19. Landa M.S., Schuman M.L., Burgueno A., Alvarez A.L., García S.I., Pirola C.J. SiRNA- -mediated silencing of the diencephalic thyrotropin-releasing hormone precursor gene decreases the arterial blood pressure in the obese agouti mice. Front. Biosci. 2007; 1: 3431–3435.
  • 20. García S.I., Landa M.S., Porto P.I. i wsp. Thyrotropin-releasin hormone decreases leptin and mediates the leptin-induced pressor eff ect. Hypertension 2002; 39: 491–495.
  • 21. García S.I., Porto P.I., Dieuzeide G. i wsp. Thyrotropin-releasing hormone receptor (TRHR) gene is associated with essential hypertension. Hypertension 2001; 38: 683–687.
  • 22. Yang H., Nyby M.D., Ao Y. i wsp. Role of brainstem thyrotropin-releasing hormone- triggered sympathetic overactivation in cardiovascular mortality in type 2 diabetic Goto-Kakizaki rats. Hypertens. Res. 2012; 35: 157–165.
  • 23. Tagliavini S., Bazzani C., Bertolini E., Bertolini A., Guarini S. TRH reverses the ECG and EEG ischemic changes induced by massive hemorrhage in rats. Life Sci. 1991; 49: 1815–1821.
  • 24. Zheng D., Chen H.S., Hu D.Y. Action of thyrotropin-releasing hormone in experimental hemorrhagic shock-cardiovascular mechanism. J. Tongji Med. Univ. 1990; 10: 187–192.
  • 25. Zheng D., Chen H.S., Hu D.Y. Cardiovascular mechanisms of thyrotropin-releasing hormone against experimental hemorrhagic shock. Circ. Shock 1992; 36: 169–173.
  • 26. Liu L.M., Hu D.Y., Chen H.S., Lu R.Q., Yan W. The importance of delta and kappa opioid receptors in the property of thyrotropin- releasing hormone against hemorrhagic shock. Shock 1997; 7: 60–64.
  • 27. Liu L., Chen H., Hu D., Lu R., Chen Y., Dan F. Opioid receptors associated with cardiovascular depressing following traumatic hemorrhagic shock in rats. Chin. J. Traumatol. 1999; 2: 48–52.
  • 28. Frithiof R., Eriksson S., Rundgren M. Central inhibition of opioid receptor subtypes and its eff ect on haemorrhagic hypotension in conscious sheep. Acta Physiol. 2007; 191: 25–34.
  • 29. Evans R.G., Ventura S., Dampney R.A., Ludbrook J. Neural mechanisms in the cardiovascular responses to acute central hypovolaemia. Clin. Exp. Pharmacol. Physiol. 2001; 28: 479–487.
  • 30. Jochem J., Jośko J., Gwóźdź B. Endogenous opioid peptides in haemorrhagic shock – central cardiovascular regulation. Med. Sci. Monit. 2001; 7: 545–549.
  • 31. Vergoni A.V., Marrama D., Guarini S. i wsp. Aff erent vagal fi bres and central cholinergic mechanisms are involved in the TRH-induced reversal of haemorrhagic shock. Pharmacol. Res. 1991; 23: 271–278.
  • 32. Jochem J. Endogenous central histamine- induced reversal of critical hemorrhagic hypotension in rats – studies with L-histidine. Shock 2003; 20: 332–337.
  • 33. Jochem J. Endogenous central histamine- induced reversal of critical haemorrhagic hypotension in rats – studies with N-methyltransferase inhibitor SKF 91488. Infl amm. Res. 2002; 51: 551–556.
  • 34. Jochem J. Involvement of the sympathetic nervous system in the reversal of critical haemorrhagic hypotension by endogenous central histamine in rats. Naunyn Schmiedebergs Arch. Pharmacol. 2004; 369: 418–427.
  • 35. Jochem J. Involvement of the renin- angiotensin system in central histamineinduced reversal of critical haemorrhagic hypotension in rats. J. Physiol. Pharmacol. 2004; 55: 39–55.
  • 36. Jochem J. Involvement of arginine vasopressin in endogenous central histamine- -induced reversal of critical haemorrhagic hypotension in rats. Infl amm. Res. 2004; 53: 269–276.
  • 37. Jochem J. Involvement of proopiomelanocortin- derived peptides in endogenous central histamine-induced reversal of critical haemorrhagic hypotension in rats. J. Physiol. Pharmacol. 2004; 55: 57–71.
  • 38. Yalcin M., Savci V., Jochem J. Involvement of the cholinergic system in the central histamine-induced reversal of critical haemorrhagic hypotension in rats. J. Physiol. Pharmacol. 2009; 60: 133–137.
  • 39. Jochem J., Żwirska-Korczala K. Interactions between the histaminergic and opioidergic systems in the central cardiovascular regulation – haemodynamic studies. Infl amm. Res. 2004; 53: S63–S64.
  • 40. Jochem J. Central histamine-induced reversal of haemorrhagic shock in rats – a comparison with the pressor eff ect of peripheral adrenergic receptor stimulation. Infl amm. Res. 2003; 52: S41–S42.
  • 41. Jochem J., Żak A., Rybczyk R., Irman- -Florjanc T. Interactions between the serotonergic and histaminergic systems in the central cardiovascular regulation in haemorrhage-shocked rats: involvement of 5-HT(1A) receptors. Infl amm. Res. 2009; 58: 38–40.
  • 42. Parmentier R., Kolbaev S., Klyuch B.P. i wsp. Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J. Neurosci. 2009; 29: 4471–4483.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-9a8ebd9e-e4e5-4551-833a-646962a6c1de
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.